NCT03615911View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

April 15, 2019

Study Completion Date

May 10, 2019

Conditions
MERS (Middle East Respiratory Syndrome)
Interventions
BIOLOGICAL

vaccine candidate MVA-MERS-S

vaccination with MVA-MERS-S in two escalating dose regimes

Trial Locations (1)

20251

CTC North GmbH & Co. KG at the University Medical Center Hamburg-Eppendorf, Hamburg

All Listed Sponsors
collaborator

Philipps University Marburg

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

collaborator

University of Cologne

OTHER

lead

Marylyn Addo

OTHER

NCT03615911 - Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S | Biotech Hunter | Biotech Hunter